scholarly journals Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jira Chansaenroj ◽  
Ritthideach Yorsaeng ◽  
Nawarat Posuwan ◽  
Jiratchaya Puenpa ◽  
Nasamon Wanlapakorn ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Multiple Time ◽  
Serum Samples ◽  
Asymptomatic Group ◽  
Seropositivity Rate ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Respiratory Specimens

AbstractThis study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r =  − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.

scholarly journals Long-term Specific IgG Response to SARS-CoV-2 Nucleocapsid Protein in Recovered COVID-19 Patients

2021 ◽  
Author(s):  
Jira Chansaenroj ◽  
Ritthideach Yorsaeng ◽  
Nawarat Posuwan ◽  
Jiratchaya Puenpa ◽  
Nasamon Wanlapakorn ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Multiple Time ◽  
Serum Samples ◽  
Asymptomatic Group ◽  
Seropositivity Rate ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Respiratory Specimens

Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N=302) or multiple time points (N=229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti‑N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P<0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P<0.01), 9 months (P=0.04), and 12 months (P=0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r=0.192, P<0.01) but negatively correlated with interval between symptom onset and blood sampling (r=−0.567, P<0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.

scholarly journals Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset

2021 ◽  
Vol 12 ◽  
Author(s):  
Tiandan Xiang ◽  
Boyun Liang ◽  
Yaohui Fang ◽  
Sihong Lu ◽  
Sumeng Li ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Neutralizing Antibodies ◽  
Natural Infection ◽  
Protein S ◽  
Igg Antibodies ◽  
Neutralizing Activity ◽  
Specific Igg ◽  
One Year ◽  
Kinetics Of

Major advances have been made in understanding the dynamics of humoral immunity briefly after the acute coronavirus disease 2019 (COVID-19). However, knowledge concerning long-term kinetics of antibody responses in convalescent patients is limited. During a one-year period post symptom onset, we longitudinally collected 162 samples from 76 patients and quantified IgM and IgG antibodies recognizing the nucleocapsid (N) protein or the receptor binding domain (RBD) of the spike protein (S). After one year, approximately 90% of recovered patients still had detectable SARS-CoV-2-specific IgG antibodies recognizing N and RBD-S. Intriguingly, neutralizing activity was only detectable in ~43% of patients. When neutralization tests against the E484K-mutated variant of concern (VOC) B.1.351 (initially identified in South Africa) were performed among patients who neutralize the original virus, the capacity to neutralize was even further diminished to 22.6% of donors. Despite declining N- and S-specific IgG titers, a considerable fraction of recovered patients had detectable neutralizing activity one year after infection. However, neutralizing capacities, in particular against an E484K-mutated VOC were only detectable in a minority of patients one year after symptomatic COVID-19. Our findings shed light on the kinetics of long-term immune responses after natural SARS-CoV-2 infection and argue for vaccinations of individuals who experienced a natural infection to protect against emerging VOC.

scholarly journals Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data

2021 ◽  
Author(s):  
Nasamon Wanlapakorn ◽  
Nungruthai Suntronwong ◽  
Harit Phowatthanasathian ◽  
Ritthideach Yorsang ◽  
Thanunrat Thongmee ◽  
...  
Keyword(s):  
Neutralizing Antibody ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Activity ◽  
Serum Samples ◽  
Real World Data ◽  
Comparison Groups ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Specific Igg ◽  
Vectored Vaccine ◽  
Sera Samples

Abstract Limited data are available on the responses to heterologous vaccine regimens for SARS-CoV-2, especially among countries using inactivated and adenoviral-vectored vaccines. A total of 77 participants who received heterologous prime/booster-inactivated COVID-19 vaccine and adenoviral-vectored vaccine were enrolled in our study. There were two comparison groups vaccinated with the homologous CoronaVac (N = 79) and AZD1222 (N = 80) regimen. All sera samples were tested for SARS-CoV-2 spike receptor-binding-domain (RBD) IgG using a chemiluminescent microparticle immunoassay (CMIA). The neutralizing activity in a subset of serum samples was tested against the original Wuhan strain and variants of concern, B.1.1.7 and B.1.351, using an enzyme-linked immunosorbent assay (ELISA)-based surrogate virus neutralization test (sVNT). The CoronaVac followed by the AZD1222 vaccine induced higher levels of spike RBD-specific IgG than that of two-dose CoronaVac or AZD1222 vaccines (p < 0.001). Sera samples of the CoronaVac/AZD1222 vaccine recipients elicited higher neutralizing antibody activity against the original Wuhan and the B.1.351 strain than in the recipients of the two-dose CoronaVac or AZD1222. Following the inactivated CoronaVac/adenoviral-vectored (AZD1222) vaccination administered 14–72 days apart, participants receiving the heterologous vaccine regimen had higher spike RBD-specific IgG and neutralizing activities than the homologous CoronaVac vaccine recipients.

scholarly journals Bioinformatics Methods for Learning Radiation-Induced Lung Inflammation from Heterogeneous Retrospective and Prospective Data

2009 ◽  
Vol 2009 ◽  
pp. 1-14 ◽  
Author(s):  
Sarah J. Spencer ◽  
Damian Almiron Bonnin ◽  
Joseph O. Deasy ◽  
Jeffrey D. Bradley ◽  
Issam El Naqa
Keyword(s):  
Multiple Time ◽  
Biological Factors ◽  
Serum Samples ◽  
Prospective Data ◽  
Lung Cancer Patients ◽  
Complex Interactions ◽  
Treatment Conditions ◽  
Dose Volume ◽  
Radiation Induced ◽  
Multiple Time Points

Radiotherapy outcomes are determined by complex interactions between physical and biological factors, reflecting both treatment conditions and underlying genetics. Recent advances in radiotherapy and biotechnology provide new opportunities and challenges for predicting radiation-induced toxicities, particularly radiation pneumonitis (RP), in lung cancer patients. In this work, we utilize datamining methods based on machine learning to build a predictive model of lung injury by retrospective analysis of treatment planning archives. In addition, biomarkers for this model are extracted from a prospective clinical trial that collects blood serum samples at multiple time points. We utilize a 3-way proteomics methodology to screen for differentially expressed proteins that are related to RP. Our preliminary results demonstrate that kernel methods can capture nonlinear dose-volume interactions, but fail to address missing biological factors. Our proteomics strategy yielded promising protein candidates, but their role in RP as well as their interactions with dose-volume metrics remain to be determined.

scholarly journals Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine

Vaccines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 82 ◽  
Author(s):  
Els van Westen ◽  
Mirjam Knol ◽  
Alienke Wijmenga-Monsuur ◽  
Irina Tcherniaeva ◽  
Leo Schouls ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Pneumococcal Disease ◽  
Booster Dose ◽  
Multiple Time ◽  
Igg Antibody ◽  
Primary Series ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Antibody Levels ◽  
Antibody Kinetics

The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease. We compared the levels of 10-valent (PCV10) and 13-valent (PCV13) pneumococcal vaccine induced serum IgG antibodies at multiple time points after primary vaccinations. Data from two separate studies both performed in the Netherlands in infants vaccinated at 2, 3, and 4 months of age with either PCV10 or PCV13 were compared. Antibody levels were measured at 5, 8, and 11 months of age, during the interval between the primary immunization series and the 11-months booster dose. Serotype-specific IgG levels were determined by multiplex immunoassay. Although antibody kinetics showed significant variation between serotypes and between vaccines for the majority of the 10 shared serotypes, i.e., 1, 5, 7F, 9V, 14, 18C, and 23F, antibody concentrations were sufficiently high for both vaccines, immediately after the primary series and throughout the whole period until the booster dose. In contrast, for serotypes 4 and 19F in the PCV10 group and for serotypes 4 and 6B in the PCV13 group, IgG antibody concentrations already come within reach of the frequently used seroprotection level of 0.35 μg/mL immediately after the primary series at the five month time point and/or at eight months. This paper addresses the importance of revealing differences in serotype-specific and pneumococcal vaccine-dependent IgG antibody patterns during the interval between the primary series and the booster dose, an age period with a high IPD incidence. Trial registration: www.trialregister.nl NTR3069 and NTR2316.

scholarly journals The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies

2021 ◽  
Author(s):  
Zheng Quan Toh ◽  
Rachel A Higgins ◽  
Jeremy Anderson ◽  
Nadia Mazarakis ◽  
Lien Anh Ha Do ◽  
...  
Keyword(s):  
Dried Blood Spots ◽  
Strongly Correlated ◽  
Serum Samples ◽  
Igg Antibody ◽  
Seropositivity Rate ◽  
Hard To Reach Populations ◽  
Specific Igg ◽  
Polymerase Chain ◽  
Paired Serum ◽  
Serum Igg Levels

Abstract Background To determine if dried blood spot specimens (DBS) can reliably detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, we compared the SARS-CoV-2 IgG antibody response in paired serum and eluates from DBS specimens. Methods A total of 95 paired DBS and serum samples were collected from 74 participants (aged 1–63 years) as part of a household cohort study in Melbourne, Australia. SARS-CoV-2 IgG antibodies specific for the receptor-binding domain (RBD) and S1 proteins between serum and eluates from DBS specimens were compared using an FDA-approved ELISA method. Results Among the 74 participants, 42% (31/74) were children and the rest were adults. A total of 16 children and 13 adults were SARS-CoV-2 positive by polymerase chain reaction. The IgG seropositivity rate was similar between serum and DBS specimens (18.9% (18/95) versus 16.8% (16/95)), respectively. Similar RBD and S1-specific IgG levels were detected between serum and DBS specimens. Serum IgG levels strongly correlated with DBS IgG levels (r = 0.99, P &lt; 0.0001) for both SARS-CoV-2 proteins. Furthermore, antibodies remained stable in DBS specimens for &gt;3 months. Conclusions DBS specimens can be reliably used as an alternative to serum samples for SARS-CoV-2 antibody measurement. The use of DBS specimens would facilitate serosurveillance efforts particularly in hard-to-reach populations and inform public health responses including COVID-19 vaccination strategies.

scholarly journals Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines

2021 ◽  
Vol 8 ◽  
Author(s):  
Hari Ram Choudhary ◽  
Debaprasad Parai ◽  
Girish Chandra Dash ◽  
Jaya Singh Kshatri ◽  
Narayan Mishra ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Healthcare Workers ◽  
Igg Antibodies ◽  
Serum Samples ◽  
History Of ◽  
Antibody Titers ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Research Facilities

Purpose: We investigated the persistence of the vaccine-induced immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Odisha who received a complete dose of either Covaxin or Covishield vaccine.Methods: This 24-week longitudinal cohort study was conducted from January to July 2021 with participants from 6 healthcare and research facilities of Odisha to understand the dynamicity of the vaccine-induced IgG antibodies against SARS-CoV-2 after the complete dose of vaccines.Results: Serum samples were collected from 614 participants during each follow-up and were tested in two chemiluminescent microparticle immunoassay (CLIA)-based platforms to detect SARS-CoV-2 antibodies both qualitatively and quantitatively. Among these participants, 308 (50.2%) participants were Covishield recipients and the rest 306 (49.8%) participants took Covaxin. A total of 81 breakthrough cases were recorded and the rest 533 HCWs without any history of postvaccination infection showed significant antibody waning either from T3 (Covaxin recipient) or T4 (Covishield recipient). The production of vaccine-induced IgG antibodies is significantly higher (p &lt; 0.001) in Covishield compared with Covaxin. Covishield recipients produced higher median anti-S IgG titer than Covaxin. No statistically significant differences in antibody titers were observed based on age, gender, comorbidities, and blood groups.Conclusion: This 6-month follow-up study documents a 2-fold and 4-fold decrease in spike antibody titer among Covishield and Covaxin recipients, respectively. The clinical implications of antibody waning after vaccination are not well understood. It also highlights the need for further data to understand the long-term persistence of vaccine-induced antibody and threshold antibody titer required for protection against reinfection.

The value of long-term angiographic follow-up following Pipeline embolization of intracranial aneurysms

2021 ◽  
pp. neurintsurg-2021-017745
Author(s):  
David C Lauzier ◽  
Samuel J Cler ◽  
Arindam R Chatterjee ◽  
Joshua W Osbun ◽  
Christopher J Moran ◽  
...  
Keyword(s):  
Intracranial Aneurysms ◽  
Post Treatment ◽  
Multiple Time ◽  
Angiographic Data ◽  
Aneurysm Occlusion ◽  
Multiple Time Points ◽  
Actionable Findings ◽  
Stent Stenosis

BackgroundFlow diversion of intracranial aneurysms with the Pipeline Embolization Device (PED) is commonly performed, but the value of long-term angiographic follow-up has not been rigorously evaluated. Here we examine the prevalence of actionable findings of aneurysm recurrence and development of in-stent stenosis in a cohort of patients that underwent long-term angiographic follow-up at multiple time points.MethodsAngiographic data from eligible patients were retrospectively assessed for aneurysm occlusion, in-stent stenosis, and aneurysm regrowth or recurrence. Patients were included in this study if they underwent angiographic imaging at 6 months post-treatment and at least one later time point.Results100% (132/132) of aneurysms occluded at 6 months remained occluded at final follow-up. 85.7% (6/7), 56.3% (27/48), and 25% (6/24) of aneurysms with entry remnant, subtotal filling, and total filling, respectively, at 6 months were completely occluded at final follow-up. 98.7% (147/149) of PED constructs that demonstrated no stenosis at 6 months demonstrated no stenosis at final angiography, while 44.4% (8/18) of PED constructs demonstrating in-stent stenosis at 6 months had resolution of stenosis on final angiography.ConclusionsAmong patients who undergo treatment of intracranial aneurysms with PED, the value of long-term angiography in patients demonstrating complete aneurysm occlusion and no in-stent stenosis on 6 month post-treatment angiography is low.

scholarly journals Self-collected oral fluid saliva is insensitive compared to nasal-oropharyngeal swabs in the detection of SARS-CoV-2 in outpatients

2020 ◽  
Author(s):  
Yukari C Manabe ◽  
Carolyn Reuland ◽  
Tong Yu ◽  
Razvan Azamfirei ◽  
Justin P Hardick ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Oral Fluid ◽  
Gingival Crevicular Fluid ◽  
Fluid Collection ◽  
Nasopharyngeal Swab ◽  
Multiple Time ◽  
Multiple Time Points ◽  
Widespread Access ◽  
Crevicular Fluid ◽  
Positive Agreement

Abstract SARS-CoV-2 pandemic control will require widespread access to accurate diagnostics. Salivary sampling circumvents swab supply chain bottlenecks, is amenable to self-collection, and is less likely to create an aerosol during collection compared to the nasopharyngeal swab. We compared rRT-PCR Abbott m2000 results from matched salivary oral fluid (gingival crevicular fluid collected in an Oracol device) and nasal-oropharyngeal (OP) self-collected specimens in viral transport media from a non-hospitalized, ambulatory cohort of COVID-19 patients at multiple time points. There were 171 matched specimen pairs. Compared to nasal-OP swabs, 41.6% of the oral fluid samples were positive. Adding spit to the oral fluid collection device increased the percent positive agreement from 37.2% (16/43) to 44.6% (29/65). The percent positive agreement was highest in the first 5 days after symptoms and decreased thereafter. All of the infectious nasal-OP samples (culture positive on VeroE6 TMPRSS2 cells) had a matched SARS-CoV-2 positive oral fluid sample. In this study of non-hospitalized SARS-CoV-2 infected persons, we demonstrate lower diagnostic sensitivity of self-collected oral fluid compared to nasal-OP specimens, a difference that was especially prominent more than 5 days from symptom onset. These data do not justify the routine use of oral fluid collection for diagnosis of SARS-CoV-2 despite the greater ease of collection. It also underscores the importance of considering the method of saliva specimen collection, and the time from symptom onset especially in outpatient populations.

Sign in / Sign up

Export Citation Format

Share Document